A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway

被引:4
|
作者
Fu, Jiahui [1 ]
Liang, Peili [2 ]
Zheng, Yingchun [3 ]
Xu, Cailing [1 ]
Xiong, Fu [3 ]
Yang, Fang [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Fetal Med & Prenatal Diag, Guangzhou, Peoples R China
[2] Longgang Dist Matern & Child Healthcare Hosp Shenz, Outpatient & Emergency Management Off, Shenzhen, Peoples R China
[3] Southern Med Univ, Sch Basic Med Sci, Dept Med Genet, Guangzhou, Peoples R China
关键词
Tuberous sclerosis complex; TSC2; Large deletion; PAM signaling pathway; Cardiac rhabdomyoma; Hypomelanotic macules; BRAIN;
D O I
10.1016/j.gene.2024.148312
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background/aim: Tuberous sclerosis complex (TSC) is a multi-system syndrome caused by loss-of-function mutation in TSC1 or TSC2. Most TSC patients present with cardiac rhabdomyoma or cortical tubers during fetal life, and the symptoms are not uniform as their age. The gene products of TSC1/2 are components of the TSC protein complex and are important role in the PI3K/AKT/mTOR (PAM) signaling pathway. Based on three members of a family with variable expressivity, the purpose of this study was to clarify the clinical features of TSC in different age groups and to analyze the genetic characteristics of TSC2 gene. Methods: Clinical exome sequencing and co-segregation were used to identify a three-generation family with four affected individuals. HEK-293T cell model was constructed for subsequent experiments. Quantitative RT-PCR, western blotting, and subcellular localization were used to analyze the expression effect of TSC2 mutation. CCK-8 assay, wound healing assay, and cell cycle analysis were used to analyze the function effect of TSC2 mutation. Result: We identified a TSC family with heterozygous deletion of exon 4 in TSC2 by clinical exon sequencing. Sanger sequencing indicated that the affected individuals have 2541-bp deletion that encompassed exon 4 and adjacent introns. Deletion of exon 4 decreased the TSC2 mRNA and protein levels in HEK-293T cells, and activated the PI3K/AKT/mTOR pathway, thereby altering the cell cycle and promoting cell proliferation and migration. Conclusion: We confirmed the pathogenicity of the large deletion in TSC2 in a three- generations family.. Deletion of exon 4 of TSC2 affected cell proliferation, migration, and cell cycle via abnormal activation of the PAM pathway. This study evaluated the pathogenic effect of deletion of exon 4 of TSC2 and investigated the underlying mechanism.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
    Dimitrova, V.
    Arcaro, A.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
  • [12] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    CANCERS, 2021, 13 (14)
  • [13] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [14] Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors
    Welker, Mark E.
    Kulik, George
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (14) : 4063 - 4091
  • [15] The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review
    Sun, K.
    Luo, J.
    Guo, J.
    Yao, X.
    Jing, X.
    Guo, F.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 (04) : 400 - 409
  • [16] The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
    Su, Hengchuan
    Gu, Yanyun
    Li, Fengying
    Wang, Qidi
    Huang, Baoxing
    Jin, Xiaolong
    Ning, Guang
    Sun, Fukang
    PLOS ONE, 2013, 8 (04):
  • [17] PI3K/Akt/mTOR signaling pathway in cancer stem cells
    Fath, Mohsen Karami
    Ebrahimi, Menooa
    Nourbakhsh, Ehsan
    Hazara, Ahmad Zia
    Mirzaei, Ali
    Shafieyari, Saba
    Salehi, Azadeh
    Hoseinzadeh, Mahsa
    Payandeh, Zahra
    Barati, Ghasem
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 237
  • [18] Targeting the PI3K/Akt/mTOR Signaling Pathway: Applications of Nanotechnology
    Serej, Forough Alemi
    Pourhassan-Moghaddam, Mohammad
    Kalan, Mohammad Ebrahimi
    Mehdipour, Ahmad
    Serej, Zeynab Aliyari
    Ebrahimi-Kalan, Abbas
    CRESCENT JOURNAL OF MEDICAL AND BIOLOGICAL SCIENCES, 2018, 5 (01): : 7 - 13
  • [19] Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
    Zhang, HB
    Cicchetti, G
    Onda, H
    Koon, HB
    Asrican, K
    Bajraszewski, N
    Vazquez, F
    Carpenter, CL
    Kwiatkowski, DJ
    JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (08): : 1223 - 1233
  • [20] PI3K/AKT/mTOR pathway in angiogenesis
    Karar, Jayashree
    Maity, Amit
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2011, 4